{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T19:23:48Z","timestamp":1788463428501,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T00:00:00Z","timestamp":1643932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T00:00:00Z","timestamp":1643932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s12094-022-02793-z","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T12:05:34Z","timestamp":1643976334000},"page":"1533-1541","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The role of stereotactic body radiotherapy in switching systemic therapy for patients with extracranial oligometastatic renal cell carcinoma"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2742-9021","authenticated-orcid":false,"given":"Cem","family":"Onal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pervin","family":"Hurmuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozan Cem","family":"Guler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guler","family":"Yavas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burak","family":"Tilki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezgi","family":"Oymak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cagdas","family":"Yavas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gokhan","family":"Ozyigit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,4]]},"reference":[{"key":"2793_CR1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"2793_CR2","doi-asserted-by":"publisher","first-page":"175","DOI":"10.6004\/jnccn.2014.0018","volume":"12","author":"RJ Motzer","year":"2014","unstructured":"Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Derweesh IH, Gupta S, et al. Kidney cancer, version 2. 2014. J Natl Compr Canc Netw. 2014;12:175\u201382.","journal-title":"J Natl Compr Canc Netw"},{"key":"2793_CR3","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.urology.2011.05.012","volume":"78","author":"SP Kim","year":"2011","unstructured":"Kim SP, Weight CJ, Leibovich BC, Thompson RH, Costello BA, Cheville JC, Lohse CM, Boorjian SA. Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma. Urology. 2011;78:1101\u20136.","journal-title":"Urology"},{"key":"2793_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"S Hellman","year":"1995","unstructured":"Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8\u201310.","journal-title":"J Clin Oncol"},{"key":"2793_CR5","doi-asserted-by":"publisher","first-page":"e549","DOI":"10.1016\/S1470-2045(14)70235-9","volume":"15","author":"S Dabestani","year":"2014","unstructured":"Dabestani S, Marconi L, Hofmann F, Stewart F, Lam TB, Canfield SE, Staehler M, Powles T, Ljungberg B, Bex A. Local treatments for metastases of renal cell carcinoma: a systematic review. Lancet Oncol. 2014;15:e549\u201361.","journal-title":"Lancet Oncol"},{"key":"2793_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.eururo.2018.09.016","volume":"75","author":"B Bhindi","year":"2019","unstructured":"Bhindi B, Abel EJ, Albiges L, Bensalah K, Boorjian SA, Daneshmand S, Karam JA, Mason RJ, Powles T, Bex A. Systematic review of the role of cytoreductive nephrectomy in the targeted therapy era and beyond: an individualized approach to metastatic renal cell carcinoma. Eur Urol. 2019;75:111\u201328.","journal-title":"Eur Urol"},{"key":"2793_CR7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.eururo.2017.03.005","volume":"72","author":"CP Meyer","year":"2017","unstructured":"Meyer CP, Sun M, Karam JA, Leow JJ, de Velasco G, Pal SK, Chang SL, Trinh QD, Choueiri TK. Complications after metastasectomy for renal cell carcinoma-a population-based assessment. Eur Urol. 2017;72:171\u20134.","journal-title":"Eur Urol"},{"key":"2793_CR8","doi-asserted-by":"publisher","unstructured":"De B, Venkatesan AM, Msaouel P, Ghia AJ, Li J, Yeboa DN, Nguyen QN, Bishop AJ, Jonasch E, Shah AY, et al. Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation. BJU Int. 2021. https:\/\/doi.org\/10.1111\/bju.15541.  (Online ahead of print).","DOI":"10.1111\/bju.15541"},{"key":"2793_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2018.04.008","volume":"98","author":"E Meyer","year":"2018","unstructured":"Meyer E, Pasquier D, Bernadou G, Calais G, Maroun P, Bossi A, Theodore C, Albiges L, Stefan D, de Crevoisier R, et al. Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: a study of the Getug group. Eur J Cancer. 2018;98:38\u201347.","journal-title":"Eur J Cancer"},{"key":"2793_CR10","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/s12094-021-02574-0","volume":"23","author":"G Marvaso","year":"2021","unstructured":"Marvaso G, Corrao G, Oneta O, Pepa M, Zaffaroni M, Corso F, Gandini S, Cecconi A, Zerini D, Mazzola GC, et al. Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how? Clin Transl Oncol. 2021;23:1717\u201326.","journal-title":"Clin Transl Oncol"},{"key":"2793_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ijrobp.2017.01.032","volume":"98","author":"CJ Wang","year":"2017","unstructured":"Wang CJ, Christie A, Lin MH, Jung M, Weix D, Huelsmann L, Kuhn K, Meyer J, Desai N, Kim DWN, et al. Safety and efficacy of stereotactic ablative radiation therapy for renal cell carcinoma extracranial metastases. Int J Radiat Oncol Biol Phys. 2017;98:91\u2013100.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2793_CR12","doi-asserted-by":"publisher","first-page":"4183","DOI":"10.1007\/s00345-021-03742-1","volume":"39","author":"Y Liu","year":"2021","unstructured":"Liu Y, Long W, Zhang Z, Zhang Z, Mai L, Huang S, Han H, Zhou F, Dong P, He L. Metastasis-directed stereotactic body radiotherapy for oligometastatic renal cell carcinoma: extent of tumor burden eradicated by radiotherapy. World J Urol. 2021;39:4183\u201390.","journal-title":"World J Urol"},{"key":"2793_CR13","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ijrobp.2019.07.023","volume":"105","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Schoenhals J, Christie A, Mohamad O, Wang C, Bowman I, Singla N, Hammers H, Courtney K, Bagrodia A, et al. Stereotactic ablative radiation therapy (SAbR) used to defer systemic therapy in oligometastatic renal cell cancer. Int J Radiat Oncol Biol Phys. 2019;105:367\u201375.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2793_CR14","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.eururo.2021.07.026","volume":"80","author":"P Cheung","year":"2021","unstructured":"Cheung P, Patel S, North SA, Sahgal A, Chu W, Soliman H, Ahmad B, Winquist E, Niazi T, Patenaude F, et al. Stereotactic radiotherapy for oligoprogression in metastatic renal cell cancer patients receiving tyrosine kinase inhibitor therapy: a phase 2 prospective multicenter study. Eur Urol. 2021;80:693\u2013700.","journal-title":"Eur Urol"},{"key":"2793_CR15","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2519::AID-CNCR26>3.0.CO;2-E","volume":"80","author":"S Ning","year":"1997","unstructured":"Ning S, Trisler K, Wessels BW, Knox SJ. Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts. Cancer. 1997;80:2519\u201328.","journal-title":"Cancer"},{"key":"2793_CR16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.prro.2013.05.001","volume":"4","author":"S Ryu","year":"2014","unstructured":"Ryu S, Pugh SL, Gerszten PC, Yin FF, Timmerman RD, Hitchcock YJ, Movsas B, Kanner AA, Berk LB, Followill DS, et al. RTOG 0631 phase 2\/3 study of image guided stereotactic radiosurgery for localized (1\u20133) spine metastases: phase 2 results. Pract Radiat Oncol. 2014;4:76\u201381.","journal-title":"Pract Radiat Oncol"},{"key":"2793_CR17","doi-asserted-by":"publisher","first-page":"e597","DOI":"10.1016\/j.ijrobp.2012.03.009","volume":"83","author":"BW Cox","year":"2012","unstructured":"Cox BW, Spratt DE, Lovelock M, Bilsky MH, Lis E, Ryu S, Sheehan J, Gerszten PC, Chang E, Gibbs I, et al. International Spine Radiosurgery Consortium consensus guidelines for target volume definition in spinal stereotactic radiosurgery. Int J Radiat Oncol Biol Phys. 2012;83:e597-605.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2793_CR18","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.semradonc.2008.04.001","volume":"18","author":"RD Timmerman","year":"2008","unstructured":"Timmerman RD. An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. Semin Radiat Oncol. 2008;18:215\u201322.","journal-title":"Semin Radiat Oncol"},{"key":"2793_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"2793_CR20","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","volume":"393","author":"DA Palma","year":"2019","unstructured":"Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393:2051\u20138.","journal-title":"Lancet"},{"key":"2793_CR21","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3109\/0284186X.2014.939298","volume":"54","author":"G Kothari","year":"2015","unstructured":"Kothari G, Foroudi F, Gill S, Corcoran NM, Siva S. Outcomes of stereotactic radiotherapy for cranial and extracranial metastatic renal cell carcinoma: a systematic review. Acta Oncol. 2015;54:148\u201357.","journal-title":"Acta Oncol"},{"key":"2793_CR22","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ctro.2019.04.012","volume":"18","author":"A Ruhle","year":"2019","unstructured":"Ruhle A, Andratschke N, Siva S, Guckenberger M. Is there a role for stereotactic radiotherapy in the treatment of renal cell carcinoma? Clin Transl Radiat Oncol. 2019;18:104\u201312.","journal-title":"Clin Transl Radiat Oncol"},{"key":"2793_CR23","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1080\/02841860600954875","volume":"45","author":"C Svedman","year":"2006","unstructured":"Svedman C, Sandstrom P, Pisa P, Blomgren H, Lax I, Kalkner KM, Nilsson S, Wersall P. A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol. 2006;45:870\u20135.","journal-title":"Acta Oncol"},{"key":"2793_CR24","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1016\/j.ijrobp.2011.02.040","volume":"82","author":"MJ Zelefsky","year":"2012","unstructured":"Zelefsky MJ, Greco C, Motzer R, Magsanoc JM, Pei X, Lovelock M, Mechalakos J, Zatcky J, Fuks Z, Yamada Y. Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2012;82:1744\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2793_CR25","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13014-015-0528-z","volume":"10","author":"B Altoos","year":"2015","unstructured":"Altoos B, Amini A, Yacoub M, Bourlon MT, Kessler EE, Flaig TW, Fisher CM, Kavanagh BD, Lam ET, Karam SD. Local control rates of metastatic renal cell carcinoma (RCC) to thoracic, abdominal, and soft tissue lesions using stereotactic body radiotherapy (SBRT). Radiat Oncol. 2015;10:218.","journal-title":"Radiat Oncol"},{"key":"2793_CR26","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.radonc.2005.03.022","volume":"77","author":"PJ Wersall","year":"2005","unstructured":"Wersall PJ, Blomgren H, Lax I, Kalkner KM, Linder C, Lundell G, Nilsson B, Nilsson S, Naslund I, Pisa P, et al. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol. 2005;77:88\u201395.","journal-title":"Radiother Oncol"},{"key":"2793_CR27","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.euo.2019.05.007","volume":"2","author":"NG Zaorsky","year":"2019","unstructured":"Zaorsky NG, Lehrer EJ, Kothari G, Louie AV, Siva S. Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies. Eur Urol Oncol. 2019;2:515\u201323.","journal-title":"Eur Urol Oncol"},{"key":"2793_CR28","doi-asserted-by":"publisher","first-page":"4512","DOI":"10.21037\/jtd.2017.10.108","volume":"9","author":"J Hoerner-Rieber","year":"2017","unstructured":"Hoerner-Rieber J, Duma M, Blanck O, Hildebrandt G, Wittig A, Lohaus F, Flentje M, Mantel F, Krempien R, Eble MJ, et al. Stereotactic body radiotherapy (SBRT) for pulmonary metastases from renal cell carcinoma-a multicenter analysis of the German working group \u201cStereotactic Radiotherapy.\u201d J Thorac Dis. 2017;9:4512\u201322.","journal-title":"J Thorac Dis"},{"key":"2793_CR29","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1186\/s40425-019-0813-8","volume":"7","author":"BI Rini","year":"2019","unstructured":"Rini BI, Battle D, Figlin RA, George DJ, Hammers H, Hutson T, Jonasch E, Joseph RW, McDermott DF, Motzer RJ, et al. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). J Immunother Cancer. 2019;7:354.","journal-title":"J Immunother Cancer"},{"key":"2793_CR30","doi-asserted-by":"publisher","first-page":"20160251","DOI":"10.1259\/bjr.20160251","volume":"89","author":"P Cheung","year":"2016","unstructured":"Cheung P. Stereotactic body radiotherapy for oligoprogressive cancer. Br J Radiol. 2016;89:20160251.","journal-title":"Br J Radiol"},{"key":"2793_CR31","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s10585-021-10131-w","volume":"38","author":"C Franzese","year":"2021","unstructured":"Franzese C, Marvaso G, Francolini G, Borghetti P, Trodella LE, Sepulcri M, Matrone F, Nicosia L, Timon G, Ognibene L, et al. The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) genitourinary study group. Clin Exp Metastasis. 2021;38:527\u201337.","journal-title":"Clin Exp Metastasis"},{"key":"2793_CR32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.amsu.2018.01.002","volume":"27","author":"M Umer","year":"2018","unstructured":"Umer M, Mohib Y, Atif M, Nazim M. Skeletal metastasis in renal cell carcinoma: a review. Ann Med Surg (Lond). 2018;27:9\u201316.","journal-title":"Ann Med Surg (Lond)"},{"key":"2793_CR33","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/ncponc0634","volume":"3","author":"BI Rini","year":"2006","unstructured":"Rini BI. Stabilization of disease in patients with metastatic renal cell carcinoma using sorafenib. Nat Clin Pract Oncol. 2006;3:602\u20133.","journal-title":"Nat Clin Pract Oncol"},{"key":"2793_CR34","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s11912-006-0041-5","volume":"8","author":"BI Rini","year":"2006","unstructured":"Rini BI. VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices. Curr Oncol Rep. 2006;8:85\u20139.","journal-title":"Curr Oncol Rep"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-022-02793-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-022-02793-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-022-02793-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T16:14:44Z","timestamp":1657815284000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-022-02793-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,4]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["2793"],"URL":"https:\/\/doi.org\/10.1007\/s12094-022-02793-z","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,4]]},"assertion":[{"value":"29 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors declare no having conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}